Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer

Masami Ueda, Tomohiro Iguchi, Takaaki Masuda, Hisateru Komatsu, Sho Nambara, Shotaro Sakimura, Hidenari Hirata, Ryutaro Uchi, Hidetoshi Eguchi, Shuhei Ito, Keishi Sugimachi, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori, Koshi Mimori

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Background/Aim: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC). Materials and Methods: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments. Results: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorageindependent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro. Conclusion: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC.

元の言語英語
ページ(範囲)2255-2263
ページ数9
ジャーナルAnticancer research
37
発行部数5
DOI
出版物ステータス出版済み - 5 1 2017

Fingerprint

Colorectal Neoplasms
Up-Regulation
Neoplasms
Glioblastoma
Growth
Real-Time Polymerase Chain Reaction
Squamous Cell Carcinoma
Cohort Studies
Immunohistochemistry
Neoplasm Metastasis
Liver
Genes
In Vitro Techniques
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer. / Ueda, Masami; Iguchi, Tomohiro; Masuda, Takaaki; Komatsu, Hisateru; Nambara, Sho; Sakimura, Shotaro; Hirata, Hidenari; Uchi, Ryutaro; Eguchi, Hidetoshi; Ito, Shuhei; Sugimachi, Keishi; Mizushima, Tsunekazu; Doki, Yuichiro; Mori, Masaki; Mimori, Koshi.

:: Anticancer research, 巻 37, 番号 5, 01.05.2017, p. 2255-2263.

研究成果: ジャーナルへの寄稿記事

Ueda, M, Iguchi, T, Masuda, T, Komatsu, H, Nambara, S, Sakimura, S, Hirata, H, Uchi, R, Eguchi, H, Ito, S, Sugimachi, K, Mizushima, T, Doki, Y, Mori, M & Mimori, K 2017, 'Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer', Anticancer research, 巻. 37, 番号 5, pp. 2255-2263. https://doi.org/10.21873/anticanres.11562
Ueda, Masami ; Iguchi, Tomohiro ; Masuda, Takaaki ; Komatsu, Hisateru ; Nambara, Sho ; Sakimura, Shotaro ; Hirata, Hidenari ; Uchi, Ryutaro ; Eguchi, Hidetoshi ; Ito, Shuhei ; Sugimachi, Keishi ; Mizushima, Tsunekazu ; Doki, Yuichiro ; Mori, Masaki ; Mimori, Koshi. / Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer. :: Anticancer research. 2017 ; 巻 37, 番号 5. pp. 2255-2263.
@article{860c7d49e12d4ea1a43bae7a1651e2e9,
title = "Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer",
abstract = "Background/Aim: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC). Materials and Methods: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments. Results: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorageindependent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro. Conclusion: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC.",
author = "Masami Ueda and Tomohiro Iguchi and Takaaki Masuda and Hisateru Komatsu and Sho Nambara and Shotaro Sakimura and Hidenari Hirata and Ryutaro Uchi and Hidetoshi Eguchi and Shuhei Ito and Keishi Sugimachi and Tsunekazu Mizushima and Yuichiro Doki and Masaki Mori and Koshi Mimori",
year = "2017",
month = "5",
day = "1",
doi = "10.21873/anticanres.11562",
language = "English",
volume = "37",
pages = "2255--2263",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer

AU - Ueda, Masami

AU - Iguchi, Tomohiro

AU - Masuda, Takaaki

AU - Komatsu, Hisateru

AU - Nambara, Sho

AU - Sakimura, Shotaro

AU - Hirata, Hidenari

AU - Uchi, Ryutaro

AU - Eguchi, Hidetoshi

AU - Ito, Shuhei

AU - Sugimachi, Keishi

AU - Mizushima, Tsunekazu

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Mimori, Koshi

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background/Aim: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC). Materials and Methods: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments. Results: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorageindependent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro. Conclusion: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC.

AB - Background/Aim: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC). Materials and Methods: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments. Results: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorageindependent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro. Conclusion: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC.

UR - http://www.scopus.com/inward/record.url?scp=85019136447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019136447&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11562

DO - 10.21873/anticanres.11562

M3 - Article

C2 - 28476790

AN - SCOPUS:85019136447

VL - 37

SP - 2255

EP - 2263

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -